Earlier reports have demonstrated that IL-33 activates the MAPK pathways in various cancer cell lines [23,41,68,69,70], and showed an IL-33/ST2-dependent NF-κB activation [45,71,72]. This evidence concerns the gene NFKB1 and cancer.